Beijing Tsinghua Changgung Hospital/School of Clinical Medicine, Tsinghua University, Beijing, 102218, China
目的 分析CDK4/6抑制剂在临床应用中所致不良反应（ADR）的特点，为临床安全用药提供参考。方法 检索维普、中国知网、万方、Web of Science、PubMed等数据库中关于CDK4/6抑制剂致ADRs的文献并进行分析。结果 CDK4/6抑制剂致ADRs的个案报道共34例；患者平均年龄约63.5岁，ADRs多发生在用药4个月内（29例，85.29%）；CDK4/6抑制剂致ADRs主要以皮肤及其附件损害（14例，41.18%）、呼吸系统损害（6例，17.65%）、肝胆系统损害（4例，11.76%）为主；经停药和/或对症治疗后达到症状好转或治愈的有31例；3例最终死亡。结论 临床使用CDK4/6抑制剂时应加强用药监测，开展多学科患者管理，而CDK4/6抑制剂的ADR发生机制尚需进一步研究。
Objective To analyze the characteristics of adverse reactions (ADR) caused by CDK4/6 inhibitors in clinical application, so as to provide reference for clinical safe drug use.Methods Web of Science, PubMed, VIP, CNKI and Wanfang databases were searched for ADRs induced by CDK4/6 inhibitor, and the collected literatures were further analyzed statistically.Results A total of 34 cases of ADRs caused by CDK4/6 inhibitors were reported. Patients were averagely about 63.5 years old. Most of the ADRs occurred within 4 months after getting CDK4/6 inhibitors (29 cases, 85.29%). ADRs caused by CDK4/6 inhibitors mainly included damage of skin and its adnexa (14 cases, 41.18%), respiratory system damage (6 cases, 17.65%), hepatobiliary system damage (4 cases, 11.76%). 31 cases were cured or improved after drug withdrawal and/or symptomatic support. Three patients died in the end.Conclusion When using CDK4/6 inhibitors in clinic, drug safety monitoring should be strengthened to alert the occurrence of ADRs. The mechanism of adverse reactions of CDK4/6 inhibitors needs to be further studied.
唐婧,安扬,赵宇薇,毛乾泰,艾超. CDK4/6抑制剂所致药物不良反应文献分析及思考[J].肿瘤药学,2023,13(4):490-497 ( in Chinese)复制